Workshop, poster and oral presentation of data given as part of the 8th Annual Antifibrotic Drug Development (AFDD) Summit
Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors
Read the original:
Cidara Therapeutics Announces $105 Million Private Placement
Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth
Excerpt from:
Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK.
See the article here:
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to...
– License of proprietary RFdiffusion-based model, RFpeptides, provides Vilya with another powerful structure prediction framework for rapid and unique design of potent and selective macrocycles for therapeutic applications
SAN MATEO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company rapidly progressing transformative therapies for viral hepatitis and other serious liver diseases, today announced the expansion of its leadership team and board of directors.
Continue reading here:
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data -
Read this article:
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
Company Announces Partnership with Rwanda Development Board to Make Affordable Treatments for Patients in Africa Company Announces Partnership with Rwanda Development Board to Make Affordable Treatments for Patients in Africa
Here is the original post:
Bio Usawa and Rwandan Government Sign a Memorandum of Understanding to Manufacture Affordable Biologics in Africa
Attributes 753% Revenue Growth to Advancing Innovative Solutions for Life Sciences, Healthcare Organizations, Payers and Patients Attributes 753% Revenue Growth to Advancing Innovative Solutions for Life Sciences, Healthcare Organizations, Payers and Patients
See original here:
AscellaHealth Ranked Number 154 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation (“Channel” or the “Company”), along with reincorporating in the State of Nevada. The Company believes the name change better reflects its focus on developing therapeutics based on sodium channel modulation and blockade for the treatment of pain.
The rest is here:
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates